New York, NY -- (SBWIRE) -- 01/17/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: Illumina, Inc. (NASDAQ:ILMN), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Twitter Inc (NYSE:TWTR), Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)
Illumina, Inc. (NASDAQ:ILMN) gained 8.52% recently, while trading on 1.50 million shares, at the price of $135.71. The stock changed hands in a range of $134.00 to $138.00 up till now, bringing its market capitalization at about $17.17 billion. If we look at its trading history of the past 52 weeks, the share price suffered a low of $48.00 and was moved to the maximum level of $138.00. Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function. Illumina provides a line of genetic analysis solutions, with products and services that serve a range of interconnected markets, including sequencing, genotyping, gene expression, and molecular diagnostics. The Company is organized in two business segments.
Why Should Investors Buy ILMN After The Recent Gain? Just Go Here and Find Out
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) added 8.16% recently, in the current trading session, at $7.28 with a total volume of 8.90 million shares. The stock, on average, trades on a volume of 28.37 million shares. It floated in a range of $7.08 to $7.35 during the recent trading session, with a beta value of 0.83. Its market capitalization now moved to about $1.34 billion. In the past 52 weeks, the share price has not declined below $2.15 or above $23.00. ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD’s first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy.
What was the Moving Force behind ARIA on Bullish Run? Read This Research Report
Twitter Inc (NYSE:TWTR) recently recorded a gain of 5.37% and was moving within a range of $63.32-$64.69, its current trading price is $63.90. The stock is moving up till now with a total volume of 6.20 million shares, versus an average volume of 28.00 million shares. The share price hit its 52-week low of $38.80 and $74.73 was the best price. Twitter, Inc. (Twitter) is a global platform for public self-expression and conversation in real time. Twitter is a real-time platform, where any user can create a Tweet and any user can follow other users. Each Tweet is limited to 140 characters of text, but can also contain rich media, including photos, videos and applications. The Company offers Twitter apps for phones, tablets and computers.
For How Long TWTR will fight for Profitability? Read This Trend Analysis report
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) added 1.79% in its current trading activity, bringing its market capitalization around $167.26 million. The share price, after opening at $1.12, hit a high of $1.18 and hovered above $1.12, while its recent trading price was $1.15. The total number of shares changed hands during the current session up till now was 1.89 million shares, as compared to average trading volume of 10.67 million shares. Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company’s pipeline features one drug candidate in Phase II clinical trials.
For How Long RNN Gloss will Attract Investors? Find out via this report
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)